Mallinckrodt Pharmaceuticals recognizes the extreme need for therapeutic options for Niemann-Pick disease type C1 (NPC), a devastating, rare neurodegenerative disease. Building on our established position in developing treatments for rare diseases, in February 2018, we […]
By Molli Salzman, Mallinckrodt employee and mother of a child with infantile spasms When my son Charlie was a baby, I had a nagging feeling something wasn’t quite right. At the time, Charlie had two […]
Author: Aaron Kirkemo, MD, senior global medical director Medical science today is making strides to better understand disease at a molecular level in order to identify more targeted ways of treating patients. As understanding of […]
Mallinckrodt employees in St. Louis and New Jersey shared a common destination this past September – a world free of Multiple Sclerosis (MS). Employees participated in the National MS Society’s Bike MS cycling event to […]